Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Multicenter, Open-label Study to Determine the Efficacy and Safety of Pomalidomide (CC-4047) in Combination With Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma and Moderate or Severe Renal Impairment Including Subjects Undergoing Hemodialysis

Trial Profile

A Phase 2 Multicenter, Open-label Study to Determine the Efficacy and Safety of Pomalidomide (CC-4047) in Combination With Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma and Moderate or Severe Renal Impairment Including Subjects Undergoing Hemodialysis

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pomalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 17 Jun 2018 Results (n=73) assessing the potential of neutrophil gelatinase-associated lipocalin as a prognostic biomarker in patients with relapsed/refractory multiple myeloma and renal impairment treated with Pomalidomide plus low dose Dexamethasone, presented at the 23rd Congress of the European Haematology Association.
    • 02 Feb 2018 Results assessing efficacy of pomalidomide plus low-dose dexamethasone (LoDEX) in patients with RRMM and moderate or severe RI, including those receiving hemodialysis, were published in the Journal of Clinical Oncology.
    • 12 Dec 2017 Results (data cut off: 28 Jan, 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top